<DOC>
	<DOCNO>NCT01144260</DOCNO>
	<brief_summary>A Study Bafetinib Treatment Patients Relapsed Refractory B-Cell Chronic Lymphocytic Leukemia ( B-CLL ) .</brief_summary>
	<brief_title>Study Bafetinib Treatment Relapsed Refractory B-Cell Chronic Lymphocytic Leukemia ( B-CLL )</brief_title>
	<detailed_description>Bafetinib dual protein kinase inhibitor , target bcr/abl Lyn kinases . B-cell chronic lymphocytic leukemia cell overexpress Lyn kinase compare normal B lymphocytes well acute leukemia ( ALL AML ) , inhibition Lyn kinase induces apoptosis culture B-CLL cell . Thus , bafetinib may stop growth B-CLL cell inhibit Lyn kinase , molecule couple B cell receptor downstream signaling .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Age ≥18 year , male female . Bcell chronic lymphocytic leukemia meeting WHO criterion . Relapsed refractory disease least one follow criterion : *progression least one course purine nucleoside analog ( fludarabine phosphate , cladribine , pentostatin ) progression least one course alkylating agent ( cyclophosphamide chlorambucil ) relapse within 12 month least one course either purine nucleoside alkylating agent . Capable provide informed consent comply trial procedure . ECOG performance status 02 . Requires chemotherapy disease show follow criterion : measurable progressive lymphocytosis measurable progressive lymphadenopathy ( lymph node ≥2 cm single diameter ) either weight loss ≥10 % within past 6 month extreme fatigue due leukemia fever ≥100.5 degree F 2 week source infection night sweat evidence infection progressive marrow failure ( worsen anemia hemoglobin &lt; 10 gm/dL and/or thrombocytopenia platelet count &lt; 100,000/mm3 ) massive progressive splenomegaly ( spleen &gt; 6 cm leave costal margin ) . Women must able become pregnant ( e.g . post menopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . [ Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ] Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . Accessibility site . Chemotherapy , antibody therapy , surgery within 4 week study enrollment . Exposure investigational agent within 30 day Screening Visit . Known CNS disease . Concurrent active malignancy except basal cell carcinoma , superficial bladder cancer carcinoma situ cervix . Laboratory value : Screening creatinine clearance ( calculate Cockcroft Gault formula ) less 50 mL/minute , alanine aminotransferase ( ALT ) great 3 time upper limit normal , total bilirubin great 3 time upper limit normal , white blood cell ( WBC ) count &lt; 3500/mm3 , absolute neutrophil count &lt; 1000/mm3 , hematocrit level &lt; 33 % female &lt; 35 % male . Clinically evident congestive heart failure &gt; class II New York Heart Association ( NYHA ) guideline . Serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. History sign active coronary artery disease without angina pectoris . Serious myocardial dysfunction define scintigraphically ( MUGA , myocardial scintigram ) ultrasound determine absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % predict . Known HIV infection . Uncontrolled active , infection . Major surgery within 3 week prior treatment . Substance abuse condition might interfere subject 's participation study evaluation study result . Any condition opinion Investigator unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>leukemia</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
</DOC>